Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 16/20 | 0.44 |
| ▸ | AURKA | O14965 | 5/20 | 0.44 |
| ▸ | KDR | P35968 | 5/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.44 |
| ▸ | TEK | Q02763 | 4/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.44 |
| ▸ | FLT4 | P35916 | 3/20 | 0.44 |
| ▸ | SRC | P12931 | 3/20 | 0.43 |
| ▸ | LCK | P06239 | 2/20 | 0.43 |
| ▸ | RET | P07949 | 2/20 | 0.43 |
| ▸ | MET | P08581 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LTK | P29376 | 2/20 | 0.43 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.43 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.43 |
| ▸ | CIT | O14578 | 1/20 | 0.43 |
| ▸ | GAK | O14976 | 1/20 | 0.43 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30428787 | 1.00 | EPHA2 (0.47) | EPHA2EGFRAURKAKDRPDGFRB | |
| SCHEMBL25215331 | 0.89 | EPHA2 (0.45) | EPHA2EGFRAURKAKDRPDGFRB | |
| SCHEMBL25213685 | 0.87 | EGFR (0.58) | EGFRKDRPDGFRBAURKBERBB2 | |
| SCHEMBL26055503 | 0.85 | EGFR (0.52) | EGFRAURKAKDRPDGFRBTEK | |
| SCHEMBL25370121 | 0.82 | TGFBR1 (0.35) | EPHA2METAXL | |
| SCHEMBL25662592 | 0.76 | EGFR (0.53) | EGFRAURKAKDRPDGFRBTEK | |
| SCHEMBL29383960 | 0.75 | TGFBR1 (0.32) | — | |
| SCHEMBL30420449 | 0.75 | EGFR (0.51) | EPHA2EGFRKDRERBB2EPHB4 | |
| SCHEMBL25663391 | 0.75 | EGFR (0.51) | EPHA2EGFRKDRERBB2EPHB4 | |
| SCHEMBL26055501 | 0.74 | EGFR (0.51) | EGFRAURKAKDRPDGFRBTEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271936-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| EP-4194443-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271936-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | EGFR, WEE1, WEE2 | EPHA2 171/4885EGFR 1/4885AURKA 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.